Skip to content

Medication patterns and complications in patients with neuropathic pain

A prospective study on prescribing patterns, drug interactions, and adverse drug reactions among patients with neuropathic pain in a tertiary care hospital - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/054518
Enrollment
363
Registered
2023-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G890- Central pain syndrome

Interventions

Intervention1: NIL: NIL

Sponsors

Jason Fernandes Joekim
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with neuropathic pain such as Diabetic neuropathy, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic inflammatory demyelinating polyradiculoneuropathy (CIDPR), Post-herpetic neuralgia, Phantom limb pain, Cervical or lumbar radiculopathy, Neuropathic postoperative pain, Trigeminal neuralgia and atypical facial pain, Nerve impingement syndromes, Alcoholic polyneuropathy, AIDS polyneuropathy, Post-traumatic neuralgia (such as nerve root compression, post-thoracotomy), Spinal cord injury (SCI), Multiple sclerosis (MS), Stroke leading to central post-stroke pain (CPSP) and Cancer chemotherapy induced neuropathic pain who are admitted to the inpatient and outpatient departments.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women as well as patients admitted due to psychiatric conditions such has anxiety, depression, PTSD, as well as patients admitted due to poisoning and accident cases were excluded from the study

Design outcomes

Primary

MeasureTime frame
The study results will give an overview of the prescription pattern of drugs & also drug-drug interaction which help in the identification of drug-related problems along with the identification & reporting of adverse drug reactions. Also, this data will be disseminated to the prescribers/clinicians which will rationalize drug therapy and enable better treatment outcomes.Timepoint: 0 15 30days

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactGrinton Josvi Veigas

Karavali College of Pharmacy, Mangalore

grin2veigas@gmail.com9901751579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026